Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.

Oncology (Williston Park, N.Y.) - 1 Feb 2014

Chu Edward

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Colorectal Neoplasms
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 24701695

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.PMID 24701695Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.Semantic proximity Read ↗

Molecular Targets for the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

EGFR-targeted therapy.Semantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.Semantic proximity Read ↗

RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.Semantic proximity Read ↗

Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.Semantic proximity Read ↗

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.